[Results of open post-registration clinical trials of copaxone in patients with multiple sclerosis].
Results of the 2-year open postregistration study of Copaxone (glatiramer acetate), conducted in 3 Moscow leading medical centres are given. 32 MS patients with remitting-relapsing MS were investigated in accordance with international requirements (neurological scales, MRI of the brain, multimodal evoked potential). Significant reduction of annual relapse rate for 70.3%, stabilization of neurological status and benign safety profile were demonstrated during Copaxone treatment. Practical recommendations for Copaxone use are given.
Zavalishin
I A
IA
Gusev
E I
EI
Iakhno
N N
NN
Ronkin
M A
MA
Shmidt
T E
TE
Demina
T L
TL
Kugoev
A I
AI
Adarcheva
L S
LS
Niiazbekova
A S
AS
Zakharova
M N
MN
Peresedova
A B
AB
Toropina
G G
GG
Klishevskaia
L A
LA
Maksimenko
I M
IM
Krotenkova
M V
MV
Konovalov
S N
SN
Rebrova
O Iu
OIu
Zhuchenko
T D
TD
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D004185:Disability Evaluation; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate